Urine Drug Testing (UDT) in Pain Management. Nov 5, 2017
|
|
- Myles Oliver
- 5 years ago
- Views:
Transcription
1 Urine Drug Testing (UDT) in Pain Management Nov 5, 2017
2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 Learning Objectives How and when to use urine drug testing (UDT) as part of a comprehensive management plan when prescribing opioids for chronic non-cancer pain Discuss how to manage unexpected UDT results
4 Urine Drug Testing (UDT) Management tool for patients treated with controlled substances or at risk for substance use May use UDT as an option for assessment and should be aware of benefits and limitations, appropriate test ordering and interpretation, and have a plan to use results
5 Prior to UDT Inform the patient Take careful history of medication/drug use in the past week Collect the sample in physicians office; ensure proper labelling
6 Point of Care Testing Rapid test performed in clinic e.g. urine dipsticks, cups Immunoassay drug screens are designed to classify substances as either present or absent according to a predetermined cut-off threshold When the amount of drug in the urine sample is equal to or exceeds the cut off concentration of a particular device, the outcome is a positive result POINT OF CARE (POC) LABORATORY TESTING COMPARISON
7 Laboratory Testing Specimen sent to laboratory Gas or Liquid Chromatography/ Mass Spectrometry is a more definitive laboratory based procedure to identify specific drug and/or metabolites and is needed in 3 instances: To specifically identify the drug; for example, that morphine is the opiate causing the positive immunoassay response To identify drugs not otherwise included in other testing To contest results disputed by the patient POINT OF CARE (POC) LABORATORY TESTING COMPARISON
8 Comparison - ADVANTAGES Point of Care -Immunoassay Rapid Results Concurrently test for multiple drug classes Very responsive for morphine and codeine Laboratory - Chromatography Identifies specific drug Confirmation of results More accurate for semisynthetic and synthetic opioids Does not cross react with poppy seeds POINT OF CARE (POC) LABORATORY TESTING COMPARISON
9 Validation Patients may tamper with urine samples to hide aberrant behaviours by: adding adulterants diluting the sample substituting another individuals sample for their own ingesting excessive water or diuretics prior to giving a sample Tests performed to improve the reliability of urine sample results NORMAL CHARACTERISTICS OF A URINE SPECIMEN Temperature (within 4 mins) Degrees Celcius ph Urinary Creatinine >20 mg/dl Specific Gravity >1.003
10 What To Do With Abnormal UDT Results: General Approach Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory (potential for false positive and false negative) Check with lab re: potential error What kind of urine test was done? Interpret results in the context of the patient s clinical presentation and assessments Possibly ask the lab to re-run the sample with chromotgraphy if response still unclear UDT, urine drug test.
11 Unexpected Results Case Table of Contents 1 Is the patient taking the opioid I prescribed? 2 I didn t prescribe that! 3 I didn t expect to find that in your urine sample! 4 Did my patient tamper with the urine sample?
12 Unexpected Results Case 1 Is the patient taking the opioid I prescribed?
13 John 39 year old male Currently taking CR oxycodone resistant to crushing 40 mg q12h for chronic back pain On duloxetine 60 mg daily for some neuropathic features with effect Using some quetiapine 25 qhs to sleep ORT score: 8 1 for age 4 for use of THC in college, enough that he failed a semester, then righted himself and graduated, now denies using any 3 for Dad having an alcohol problem; folks split up when he was young due to it.
14 14
15 You do a routine urine on visit today Shows THC Negative for oxycodone, TCAs, benzodiazepines Now what do you do?
16 Would you? A) Fire him as he is lying to you? B) Tell him that you can no longer prescribe opioids as he is not taking them anyways? C) Confront him about the THC? D) Check when he last took CR oxycodone resistant to crushing? E) Call the lab to check the results? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory
17 Available at: Interpreting Unexpected Results of Urine Drug Screens Unexpected Result UDS negative for prescribed opioid Possible Explanations False negative Non-compliance Diversion Actions for the Physician Table B-3.1 Repeat test using chromatography; specify the drug of interest (e.g. oxycodone often missed by immunoassay) Take a detailed history of the patient s medication use for the preceding 7 days (e.g. could learn that patient ran out several days prior to test) Ask patient if they ve given the drug to others Monitor compliance with pill counts
18 John Restarted marijuana use and problems at work and home Financial issue selling CR oxycodone and some quetiapine CR oxycodone discontinued (should this be tapered?) Quetiapine prescribing decreased to 7days supply Offered resources for drug counselling and treatment programs Revised ORT score - High Risk Regular and random UDT
19 Unexpected Results Case 2 I didn t prescribe that!
20 Mary 66 year old female Spinal stenosis 2 failed surgeries in 1999 and 2006 Intolerant of NSAIDS/ COX-2 No personal of family history of drugs or alcohol No history of mental health issues
21 Mary Has taken acetaminophen 650 QID on a regular basis Reports constipation with acetaminophen/codeine 30mg (not filled Rx in 1 year) Reports significantly decreased QoL over last 6 months After exhausting more physical and psychological modalities, you are considering a trial of oxycodone 5mg
22 Mary Baseline UDT recommendation roadmap Do this on everyone UDS immunoassay is positive for benzodiazepines and opioids
23 Mary Now what do you do? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory
24 Available at: Interpreting Unexpected Results of Urine Drug Screens Table B-3.1 Unexpected Result Possible Explanations Actions for the Physician UDS positive for nonprescribed opioid or benzodiazepines False positive. Patient acquired opioids from other sources (doubledoctoring, street ) Repeat UDS regularly Ask the patient if they accessed opioids from other sources Assess for opioid misuse/addiction (See Guideline, Part B, Recommendation 12) Review/revise treatment agreement
25 Known Agents To Cause Interference in Urine Drug Test Results Opioids Marijuana Cocaine Amphetamines Benzodiazepines Dextromethorphan Diphenhydramine (methadone assay only) Poppy seeds Quinine Quinolone antibiotics Rifampin Verapamil (methadone assay only) Efavirenz Hemp seed NSAIDs PPIs Tolmetin Coca leaf tea Amantadine Bupropion Chlorpromazine Desipramine Labetalol Methylphenidate Phentermine Phenylephrine Pseudoephedrine Ranitidine Selegiline Tolmetin Trazodone Typical antipsychotics Oxaprozin Sertraline NSAID, non-steroidal anti-inflammatory drug. PPI, proton pump inhibitor. Adapted from Peppin JF, et al. Pain Med 2012;13: , Reisfield et al Ann Clin Lab Med 1997, Piergies et al Arch Path Lab Med 1997
26 Mary Explanation of Mary's results: Benzodiazepines: Occasionally takes her sisters diazepam 5mg pills Uses acetaminophen/codeine 8mg on a regular basis (up to 8 per day)
27 Mary Explanation of Mary's results: Benzodiazepines: Diazepam metabolizes to nordiazepam, temazepam and oxazepam. Opioids Codeine metabolizes to morphine
28 Benzodiazepines and Opioids Increases the risk of sedation, overdose, and diminished function in all patients, especially as age advances Benzodiazepines increase opioid toxicity and risk of overdose Canadian Guideline for Safe and Effective Use of Opioids for CNCP Part B
29 Mary The presence of a substance that we are not expecting to find can be used to educate patients on safety of drug interactions and toxicity Mary was counseled on the danger of acetaminophen toxicity and use of benzodiazepines Additional counseling points: Definition of misuse Information on safe storage, no sharing, safe disposal, etc. Opioid Treatment Agreement
30 Mary Treatment Plan Not start oxycodone prescriptions for now Explore reasons for benzodiazepine use and possible nonbenzodiazepine treatments for this (medication, psychological, behavioural) Repeat urine test in 3-4 weeks to ensure benzodiazepines are now negative (diazepam can remain positive for 3 weeks) Ensure Mary's daily acetaminophen intake is below a level of concern
31 Unexpected Results Case 3 I didn t expect to find that in your urine sample!
32 Frank 34 year old male C6-7 fracture from snowmobile accident subsequent fusion C5 to T1 PMHx ADD SHx Recently separated with 2 children Smoker 1 ppd ETOH max 3 per day and 15 per week Denies street drug use FHx mental illness - ADD
33 Frank Meds Oxycodone-acetaminophen 1-2 Q4h PRN 8 per day Meloxicam 15mg PO Qdaily Tx No change with physio, chiro, acupuncture VAS Neck pain 8/10 radiating to trapezius and shoulder bilaterally
34 Frank CAGE-AID Low Risk Opioid Risk Tool 4/7 moderate risk Male age Hx of ADD 2 Current depression 1
35 Assessment UDS immunoassay in office Opiates EDDP Oxycodone Cocaine TCA - negative negative positive positive negative Now what do you do? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory
36 Available at: Interpreting Unexpected Results of Urine Drug Screens Table B-3.1 Unexpected Result Possible Explanations Actions for the Physician UDS positive for illicit drugs (e.g. cocaine, cannabis) False positive Patient is occasional user or addicted to the illicit drug Cannabis is positive for patients THC:CBD (Sativex ) or using medical marijuana Repeat UDS regularly Assess for abuse/addiction and refer for addiction treatment as appropriate Ask about medical prescription of THC:CBD or medical marijuana access program
37 Known Agents To Cause Interference in Urine Drug Test Results Opioids Marijuana Cocaine Amphetamines Benzodiazepines Dextromethorphan Diphenhydramine (methadone assay only) Poppy seeds Quinine Quinolone antibiotics Rifampin Verapamil (methadone assay only) Efavirenz Hemp seed NSAIDs PPIs Tolmetin Coca leaf tea Amantadine Bupropion Chlorpromazine Desipramine Labetalol Methylphenidate Phentermine Phenylephrine Pseudoephedrine Ranitidine Selegiline Tolmetin Trazodone Typical antipsychotics Oxaprozin Sertraline NSAID, non-steroidal anti-inflammatory drug. PPI, proton pump inhibitor. Adapted from Peppin JF, et al. Pain Med 2012;13: , Reisfield et al Ann Clin Lab Med 1997, Piergies et al Arch Path Lab Med 1997
38 Frank Admitted to cocaine use intermittently Offered resources for drug counselling and treatment programs Revised ORT score - High Risk Regular and random UDT Treated with non opioid pharmaceuticals and modalities; or Structured opioid treatment with tight boundaries
39 Random UDTs When a patient steps out of bounds Explain need for good communication system patient cell # or answering system After seeing pt, choose some random dates and record on chart Receptionist writes down in a daily TO-DO list and calls pt by 10:00am to come in Patient has 24hrs to comply or violation
40 What if? He does not admit to the use? Denies it vehemently? Gets angry and defensive? What are your next options?
41 Unexpected Results Case 4 Did my patient tamper with the urine sample? If there is a will, there is a way Misuse, Abuse, and Diversion of prescription medications are great motivators to tamper with a UDT
42 Emma 57 year old female Chronic low back pain Diabetic polyneuropathy Rx with fentanyl transdermal patch 50ug/72 hours Pregabalin 150mg BID Nortriptyline 25mg for sleep and pain
43 Emma ORT Low Score of 2 as son has a history of drug abuse Opioid treatment agreement signed Never asks for early refills Never loses meds Random UDT annually negative for illicit drugs Always negative for fentanyl but active patch and old patch remnants seen on body
44 Emma Annual UDT January 2016 Negative for illicit drugs Negative for opioids Negative for fentanyl Specific Gravity (Normal is )
45 Emma Is Emma taking her fentanyl? Has her urine sample been tampered with? How else can you test for tampering? How do you address any concerns with Emma? Now what do you do? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory
46 Interpreting Unexpected Results of Urine Drug Screens Table B-3.1 Unexpected Result Possible Explanations Actions for the Physician Urine creatinine is lower than 2-3 mmol/liter (>20 mg/dl), specific gravity is <1.003 or sample is cold Patient added water to sample Delay in handling sample (urine cools within minutes) Repeat UDS Consider supervised collection or temperature testing Take a detailed history of the patient s medication use for the preceding 7 days Review/revise treatment agreement Available at:
47 Validation Patients may tamper with urine samples to hide aberrant behaviours by: adding adulterants diluting the sample substituting another individuals sample for their own ingesting excessive water or diuretics prior to giving a sample Tests performed to improve the reliability of urine sample results NORMAL CHARACTERISTICS OF A URINE SPECIMEN Temperature (within 4 mins) Degrees Celcius ph Urinary Creatinine >20 mg/dl Specific Gravity >1.003
48 Emma Repeat UDS supervised if possible (female staff to observe) Emma admits that she is only using acetaminophen/codeine 8mg Her son (a known drug abuser) has been stealing her fentanyl patches and usually makes sure she has a new patch on the day before she sees you What do you do now?
49 Emma Discuss medication safety with Emma? Alternate plans for storage, or daily dispensing Consider changing medication to lower abuse risk or ingested with daily dispensing? Consider personal safety ramifications for Emma? Offer resources for support and safety plan. Consider legal issues in regards to the son? Plans may include other community resources. Consider Emma s safety in dealing with her son. Review patient responsibilities regarding the Opioid treatment agreement
50 Summary UDS is a recommendation in The Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain UDS point of care immunoassay and laboratory chromatography have different advantages/disadvantages and limitations Your first action with an unexpected result should be Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory Each type of unexpected result has a DDx and appropriate physician actions
Urine Drug Testing (UDT) to Monitor Opioid Use. Feb 2018
Urine Drug Testing (UDT) to Monitor Opioid Use Feb 2018 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationUrine Drug Testing (UDT) in Pain Management. Nov 27, 2017
Urine Drug Testing (UDT) in Pain Management Nov 27, 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationPrescribing Opioid for. Opioid Naïve Patients AN OPIOD RX
Prescribing Opioid for Opioid Naïve Patients AN OPIOD RX Optimal Approach to Initiating Opioids for Chronic Non-Cancer Pain AN OPIOID RX Assessment biopsychosocial Non-opioid treatments Opioid risks vs.
More informationUrine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
More informationThe Utility of Urine Drug Screening
The Utility of Urine Drug Screening Treating Addiction, Saving Lives Sea Cruises Bye Tazmania, still far from New Zealand February 8 th, 2018 Mandy Manak, MD FASAM, ISAM, CSAM, MRO Medical Director, ICDO
More informationUrine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017
Urine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any
More information3/8/2018. Reasons for Doing UDT. UDT: A Tool in Risk Assessment. Faculty/Presenter Disclosure. Urine Drug Testing in Chronic Pain Management
Urine Drug Testing in Chronic Pain Management March 8, 2018 Faculty/Presenter Disclosure Faculty: Andrew J Smith, MDCM Relationships with commercial interests: None to report Andrew J Smith, MDCM Staff
More informationControlled Substance Monitoring in the Age of the Opioid Epidemic
Controlled Substance Monitoring in the Age of the Opioid Epidemic Paul E. Hilliard, MS, MD Hospital Pain Committee Chair Department of Anesthesiology CME housekeeping I have no financial disclosures AKA,
More informationControlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing
Controlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing Mississippi Primary Health Care Association Pearl, MS March 7, 2018 Scott Hambleton, MD, DFASAM Medical
More informationTesting for Controlled Substances
Testing for illicit drugs Testing for Controlled Substances 1 Purposes: Employment Sports Screening medical eval. Legal Monitoring Treatment Probation Prescribing controlled substances Forensics 2 Drug
More informationUrine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016
Urine Drug Testing Methadone/Buprenorphine 101 Workshop Ron Joe, MD, DABAM December 10, 2016 Learning objectives Clarify the purpose of urine drug testing (UDT) Distinguish between UDT for detection of
More information10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?
Objectives Drug Testing Interpretation in Addiction Care Brandi Puet, Pharm.D. Describe the difference between immunoassay and confirmatory testing. List explanations for unexpected negative or positive
More informationFrequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up
Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Dr. Bhushan M. Kapur Associate Professor Department of Laboratory Medicine and Pathobiology, Faculty
More informationApproaches to Responsible Opioid Prescribing. The Opioid Naïve Patient
Approaches to Responsible Opioid Prescribing The Opioid Naïve Patient Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with
More informationOverview. Opioids and HIV Infection: From Pain Management to Addiction Treatment
FORMATTED: 01/23/2017 New York, New York: February 24, 2017 Opioids and HIV Infection: From Pain Management to Addiction Treatment Chinazo Cunningham, MD, MS Professor of Medicine Albert Einstein College
More informationURINE DRUG TOXICOLOGY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences URINE DRUG TOXICOLOGY Suzanne E. Rapp, MD GENERAL DISCLOSURES The University of Washington School of Medicine also
More informationUrine Drug Testing to Monitor Opioid Use In Managing Chronic Pain
Faculty Disclosure Henry C. Nipper, PhD, DABCC Dr. Nipper has listed no financial interest/arrangement that would be considered a conflict of interest. Urine Drug Testing to Monitor Opioid Use In Managing
More informationPhysician s Reference for Urine and Blood Drug Testing and Interpretation
Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine
More information1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)
Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program North Sydney April 12, 2018 This speaker has been asked to disclose to the audience any involvement with
More informationPROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN
PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN 1 OPIOID USE DISORDER IN WOMEN Recognition & Prevention Date: August 14 th, Time: 8 am Presenters: Deepa Nagar MD, Andria Peterson PharmD Maternal Treatment
More informationDisclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17
You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies Jeffrey Fudin, BS, PharmD, FCCP, FASHP www.paindr.com Disclosures Astra Zeneca (Speakers Bureau) Collegium (Consultant) Daiichi
More informationWelcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017
Welcome! Supreme Court of Ohio Specialized Dockets Conference October 23-24, 2017 Drug Testing: Do you know enough to be dangerous? Presented by William L. Parker President & CEO American Court & Drug
More informationCaring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, PM
Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, 2018 12 1 PM Audio is available through your computer speakers. Mission Maine Quality Counts is a nonprofit
More informationPatient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM
Patient-Centered Urine Drug Testing Douglas Gourlay, MD, MSc, FRCPC, FASAM Declaration of Potential Conflict of Interest The content of this presentation is non- commercial and does not represent any conflict
More informationSeptember HCMC Toxicology Transition: Additional information and Frequently Asked Questions
September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch
More informationRecognizing Narcotic Abuse and Addiction and Helping Those With It
Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved
More informationCorporate Medical Policy
Corporate Medical Policy Drug Testing in Pain Management and Substance Abuse Treatment File Name: Origination: Last CAP Review: Next CAP Review: Last Review: drug_testing_in_pain_management_and_substance_abuse_treatment
More informationGold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine?
Gold Standard for Urine Drug Testing Developed by TRMC Pain Management Center Jill Duffy, RN,BC Pam Kennell, RN, BC Heidi Beisch, RN Urine Drug Testing A DIAGNOSTIC tool For an OBJECTIVE test Based on
More informationUrine drug testing it s not always crystal clear
Urine drug testing it s not always crystal clear Kirk Moberg, MD, PhD, FASAM Executive Medical Director, UnityPoint Health Illinois Institute for Addiction Recovery Clinical Professor of Internal Medicine
More informationLearning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly
Utilization of the urine drug screen: The good, the bad, and the ugly Jennifer A. Lowry, MD Chief, Section of Medical Toxicology Children s Mercy Hospital Kansas City, MO Learning Objectives Describe the
More informationChronic Opioid Therapy Safe Prescribing in Primary Care. Part 3
Chronic Opioid Therapy Safe Prescribing in Primary Care Part 3 Michael Mangione, MD Chief of Anesthesia and Director of Pain Service VA Pittsburgh Health Care System Nancy Wiedemer,CRNP VISN 4 Pain Management
More informationBest Practices in Prescribing Opioids for Chronic Non-cancer Pain
Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G
More informationGoals decided with patient: Mild-to-Moderate Pain First- line: codeine or tramadol Second-line: morphine, oxycodone or hydromorphone
The Opioid Manager is designed to be used as a point of care tool for providers prescribing opioids for chronic non cancer pain. It condenses key elements from the ACanadian Opioid Guideline and can be
More informationDrug Testing in Pain Management and Substance Use Disorder Treatment
Drug Testing in Pain Management and Substance Use Disorder Treatment Policy Number: 2.04.98 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationPayment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:
Payment Policy: Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationDrug Screening. Separating Facts from Myths
Drug Screening Separating Facts from Myths Today s Presenter: Todd Shoulberg, EVP ClearStar Medical Information Services Todd Shoulberg, Executive Vice President of Medical Information Services for ClearStar,
More informationConflict of Interest Disclosure
Patient Rx Drug Misuse and Abuse: Compliance Toxicology Monitoring in Clinical Practice Toxicology Staff Andrea Terrell, Ph.D., DABCC Chief Scientific Officer George Behonick, Ph.D., DABFT, Manager, FBU
More informationJennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of Toronto
Team Based Approaches to Chronic Pain Management: Opioid Stewardship Jennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of
More informationOrganizing your Practice for Efficient Pain Assessment. Session #4 Roman D. Jovey, MD
Organizing your Practice for Efficient Pain Assessment Session #4 Roman D. Jovey, MD 2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationHow Can a Methadone and an Opiate-Positive Immunoassay Result be Reconciled in a Patient Prescribed only OxyContin and Wellbutrin?
190 Available online at www.annclinlabsci.org How Can a Methadone and an Opiate-Positive Immunoassay Result be Reconciled in a Patient Prescribed only OxyContin and Wellbutrin? Jude M. Abadie Department
More informationWhat Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital
What Your Drug Test Really Means Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital Disclosure There are no relevant financial relationships with commercial interests associated.
More informationClinical contracts. Dr. Johan Wouterloot Prescribers Course April 28, 2017
Clinical contracts Dr. Johan Wouterloot Prescribers Course April 28, 2017 Why? Ameliorates power imbalance States a goal for the agreed upon activity Allows for contingency management to keep behaviour
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationCutoff levels for hydrocodone in a blood test
Cutoff levels for hydrocodone in a blood test The premier DNA and drug testing company in the North Texas area. Specializing in legal cases but also provide testing for employers and private individuals.
More informationScreening Pregnant and Postpartum Women for Substance Use Disorder. MPQC Fall Summit November 14, 2018
Screening Pregnant and Postpartum Women for Substance Use Disorder MPQC Fall Summit November 14, 2018 Disclosures No relevant financial or non-financial relafonships Screening Pregnant and Postpartum Women
More informationPain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine
Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationYou Can t Fool the Bladder Police. Effective Use of Urine Drug Screening
You Can t Fool the Bladder Police Effective Use of Urine Drug Screening Why Test? Accountability Create and maintain safe treatment environment Compliance with licensing or policy Collection Supervised
More informationUniversal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?
Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationDrug Testing: How to Evaluate Results
Drug Testing: How to Evaluate Results Prepared for you by the West Virginia Drug Testing Laboratory Drug testing, whether for an individual or a large corporation, consists of two necessary steps - specimen
More informationMedical Policy. MP Drug Testing in Pain Management and Substance Use Disorder Treatment
Medical Policy BCBSA Ref. Policy: 2.04.98 Last Review: 12/20/2018 Effective Date: 12/20/2018 Section: Medicine Related Policies 2.01.30 Biofeedback as a Treatment of Chronic Pain 5.01.16 Intravenous Anesthetics
More informationChronic Pain Pharmacist role in the clinic
Chronic Pain Pharmacist role in the clinic WSPA Annual Meeting 2015 Alvin Goo, PharmD Clinical Associate Professor University of Washington Schools of Pharmacy and Family Medicine Speakers Declaration
More informationLaboratory Testing to Support Pain Management: Methods, Concepts and Case Studies
Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories
More informationnextgen precision Test Report
nextgen precision TM Test Report SUMMARY OF PRECISION S NEXTGEN TEST REPORT In an effort to provide as much clinical insight as possible to our providers, we created our comprehensive NextGen Precision
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More information9/17/2014. Monitoring Controlled Substances. Objectives. Presription Painkiller Overdose
Monitoring Controlled Substances Nicole Paterson, PharmD BCPS And Michelle Herr, PharmD MTM Pharmacists 9/12/2014 Objectives Describe why we care about controlled substances Provide a few guidelines on
More informationAppropriate Prescribing of Opioids for Chronic Non Cancer Pain
Appropriate Prescribing of Opioids for Chronic Non Cancer Pain Dr. Cheri Olson La Crosse Mayo Family Medicine Residency Assistant Professor of Family Medicine, Mayo Graduate School of Medicine Disclosure
More informationEDUCATIONAL COMMENTARY METHADONE
EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education
More informationObjectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.
1/25/17 PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. PISA Physicians Kenneth B. Gossler M.D. Education University of Arizona Med School 1992. THMEP Intern 1993 Anesthesiology Residency at Financial
More informationA Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen
Section Editor: Kelly M. Smith, PharmD, BCPS, FASHP, FCCP A Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen E. Claire Markway, PharmD; Stephanie N. Baker, PharmD, BCPS Abstract:
More informationDisclosures. Preventing, Recognizing and Managing Opiate Use Disorders. Opioids in the US 10/13/17
Disclosures Preventing, Recognizing and Managing Opiate Use Disorders n None Katherine Julian, M.D. Professor of Medicine UCSF Division of General Internal Medicine October 13, 2017 Opioids in the US n
More informationDrug Screening: Things You Need to Know
Drug Screening: Things You Need to Know (a view inside the clinical laboratory) Gary L. Horowitz, MD Director, Clinical Chemistry, Beth Israel Deaconess Medical Center Associate Professor of Pathology,
More informationMEDICAL POLICY Drug Testing
POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each
More informationUrine Drug Screening: A Valuable Office Procedure
Page 1 of 12 American Family Physician Return to Previous Page Mar 1, 2010 Table of Contents Urine Drug Screening: A Valuable Office Procedure JOHN B. STANDRIDGE, MD; STEPHEN M. ADAMS, MD; and ALEXANDER
More informationTreatment Agreements Clinical Contracts. Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017
Treatment Agreements Clinical Contracts Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017 Faculty/presenter disclosure Presenter: Dr. Paul Farnan Relationships
More informationEDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing
EDUCATIONAL COMMENTARY 2003 3 rd TEST EVENT Chemistry Urine Drug Testing Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationPROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015
Matthew H. Mead Governor State of Wyoming Department of Workforce Services DIVISION OF WORKERS COMPENSATION 1510 East Pershing Boulevard, South Wing Cheyenne, Wyoming 82002 http://www.wyomingworkforce.org
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationTITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE:
TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: 4.19.16 LAST REVISED DATE: 4.19.16 LAST REVIEWED DATE: 4.19.16 Table of Contents 1. How do I conduct my first few visits with a patient who
More informationDrug & Alcohol Testing in. Canada. Point of Care Testing
Drug & Alcohol Testing in Canada Point of Care Testing Introduction We are the leading Canadian innovator of diagnostic testing products and services Verify Diagnostics has assisted governments, corporations,
More informationUrine Drug Testing In Pain Management and Substance Abuse Treatment Corporate Medical Policy
Urine Drug Testing In Pain Management and Substance Abuse Treatment Corporate Medical Policy File Name: Urine Drug Testing in Pain Management and Substance Abuse Treatment File Code: UM.SPSVC.09 Last Review:
More informationGuidelines for Urine Drug Monitoring for the Pain Patient in a Clinical Practice
Guidelines for Urine Drug Monitoring for the Pain Patient in a Clinical Practice Howard A. Heit, M.D., F.A.C.P., F.A.S.A.M. Board Certified in Internal Medicine and Gastroenterology/Hepatology Certified
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationBeating Drug Tests and Defending Positive Results
Beating Drug Tests and Defending Positive Results Amitava Dasgupta Beating Drug Tests and Defending Positive Results A Toxicologist s Perspective Amitava Dasgupta Department of Pathology and Laboratory
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationOpioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018
Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Disclosures None Educational Objectives Understand CA state medical board guidelines for prescribing opioids for chronic pain Understand the
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationStriking a Balance: a provider perspective.
Striking a Balance: a provider perspective kpfeifer@chcf.org Beth s story 38 years old, erratically employed Counseling doesn t help Chronic low back pain after car accident 8 Vicodin/day grew to 180 mg
More informationPain Medication Management Program Supports Patient Outcomes and Adherence
PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety
More informationDepartment of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA
Department of Veterans Affairs Network Policy No.: 2014-01 VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To
More informationUsing Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population
Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationMedical Affairs Policy
Medical Affairs Policy Service: Urine Drug/Alcohol Screening and Testing PUM 250-0013-1803 Medical Policy Committee Approval 03/06/18 Effective Date 07/01/18 Prior Authorization Needed No Disclaimer: This
More informationMEDICAL POLICY Drug Testing
POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 04/10/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each
More informationORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS
ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationBill McCarberg, MD. Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired)
Pain Management Bill McCarberg, MD Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired) Adjunct Assistant Clinical Professor University of California School of Medicine San Diego
More informationROLE PLAY #1: ASSESSMENT WITH THE 6 A s PATIENT ROLE
ROLE PLAY #1: ASSESSMENT WITH THE 6 A s PATIENT ROLE You are a 58 year old man/woman and have a history of severe chronic low back pain for 20 years. You injured your back 20 years ago at work and have
More informationURINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT
Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-47 Effective Date: 07/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More information2012 DRUG RELATED DEATH STATISTICS JANUARY 1, 2012 THROUGH DECEMBER 31, 2012
JANUARY 1, 2012 THROUGH DECEMBER 31, 2012 All deaths counted in the column labeled ACCIDENTAL OVERDOSE were the direct result of the drugs ingested by the decedent. The drugs noted as being present came
More informationPain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
More information